Uttarakhand licencing authority filed an affidavit in the Supreme Court on Monday stating that it had suspended licenses of 13 products manufactured by Divya Yoga Pharmacy in connection with the misleading advertisements case
The Uttarakhand licencing authority on Monday suspended the manufacturing licences of 14 Patanjali products with immediate effect, citing misleading advertisements. Of the 14, 13 products are of Divya Yoga Pharmacy, a subsidiary of Patanjali.
The licencing body filed an affidavit in the Supreme Court stating that it had suspended licenses of 13 products manufactured by Divya Yoga Pharmacy in connection with the misleading advertisements case.
Read More: Telangana CM Revanth Reddy Gets Delhi Police Notice In Amit Shah’s Doctored Video Case
WHICH PATANJALI PRODUCTS ARE FACING ACTION?
The products by Divya Yoga Pharmacy facing action include –
- Drishti Eye drop
- Swasari Gold
- Swasari Vati
- Bronchom
- Swasari Pravahi
- Swasari Avaleh
- Mukta Vati Extra Power
- Lipidom
- Bp Grit
- Madhugrit
- Madhunashini Vati Extra Power
- Livamrit Advance
- Livogrit
- Eyegrit Gold
Read More: Why Chandrayaan-3 lift-off was delayed by 4 seconds? ‘Close approach risk,’ reveals ISRO new report
The move follows legal challenges facing Ramdev’s enterprises amid allegations of false claims regarding traditional Ayurvedic medicines sold by Patanjali Ayurveda.
The Supreme Court has pulled Baba Ramdev for not complying with its directives in an ongoing case to stop misleading advertisements of some of his traditional Ayurvedic medicines. The manufacturing permits of Ramdev’s companies were suspended in an April 15 order by the drug regulator of traditional medicines in Uttarakhand.
MISLEADING ADVERTISEMENTS CASE AGAINST PATANJALI AYURVEDA
On February 27 this year, the court issued a contempt notice to Yoga Guru Baba Ramdev and his associate Acharya Balkrishna for engaging in distributing misleading health cure advertisements and barring Patanjali from promoting products with unsubstantiated claims of curing diseases like heart conditions and asthma.
Read More: Indian ecommerce market to grow to $325 billion; digital economy to reach $800 billion by 2030
Patanjali Ayurveda had issued an apology on April 22 while stating that they would not commit any such mistake in the future.
During the last hearing on April 23, the Supreme Court, while hearing a contempt case, asked Ramdev whether the size of the apology was the same as its advertisements.
On April 24, Patanjali Ayurveda co-founders Yoga guru Ramdev and Balkrishna had issued a new public apology in newspapers.
The Supreme Court will hear the matter related to the apology published by Baba Ramdev and his associate Acharya Balkrishna in connection with the case of the misleading advertisement against Patanjali Ayurveda on Tuesday.
